MedImmune
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, MedImmune sits in the top decile of US sponsors by registered trial count (#151 of 15,742 sponsors by registered trial count).
MedImmune: 210 sponsored US clinical trials, none currently recruiting.
MedImmune sponsors 210 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 185 completed. 27 of these trials are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 9 trials.
Top-decile sponsor footprint
MedImmune ranks in the top decile of sponsors by registered trial count (#151 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
185 of 203 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
210 total, page 4 of 5
Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age
NCT00493285
A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528
NCT00483041
A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus
NCT00482989
A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia
NCT00586924
A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults
NCT00480155
A Phase 2 Study to Evaluate Immune Responses of FluMist®
NCT00461981
A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness
NCT00435227
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia
NCT00587457
A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness
NCT00421304
A Sequential Dose-Escalation Study in Subjects With Mild Asthma
NCT00512486
Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants
NCT00384462
An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants
NCT00369759
Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children
NCT00345670
Study To Evaluate the Safety of Bivalent Vaccine
NCT00325481
A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children
NCT00344305
Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)
NCT00299819
Study to Assess the Immune Reactivity of the Liquid and Lyophilized Formulations of Palivizumab (MEDI-493, Synagis)
NCT00233064
A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
NCT00538785
Safety Study to Evaluate FluMist in Immunocompromised Children
NCT00112112
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
NCT00125944
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528
NCT00116168
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma
NCT00126646
Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma
NCT00111696
Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)
NCT00111579
Study to Evaluate MEDI-534 in Healthy Adults
NCT00111878
Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia
NCT00105313
MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States
NCT00121108
Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children
NCT00129766
Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program
NCT00192218
Trivalent, Live, Cold Adapted Influenza Vaccine (CAIV-T) Against Inactivated Influenza Vaccine (TIV) in Children 6-59 Months of Age
NCT00128167
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
NCT00192127
Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers
NCT00192296
Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants
NCT00192335
Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia
NCT00086099
Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age
NCT00192140
Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease
NCT00123942
Study to Evaluate the Human Infection of the Lower Respiratory Tract in Children at High Risk
NCT00192439
MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer
NCT00072930
Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis
NCT00192517
Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
NCT00081315
Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults
NCT00192465
BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia
NCT00074048
A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults
NCT00113880
Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate
NCT00069017
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
NCT00066196
A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)
NCT00240929
Long-Term Follow-Up Study of Psoriasis Patients
NCT00131066
Study to Evaluate the Safety of a Monovalent Vaccine of a New 6:2 Reassortant in Healthy Adults (AV024)
NCT00240877
Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.
NCT00192309
Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children
NCT00192322
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 106 |
| Phase 2 | 58 |
| Phase 3 | 12 |
| Phase 4 | 15 |
How the MedImmune early-phase archive is shaped
210 indexed studies, none listed as recruiting (0% open); 185 completed (88%).
Phase mix: 27 late (III/IV) vs 164 early (I/II) (early-phase heavy).
Top condition: Healthy (9 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
MedImmune: archived-pipeline peers nationwide
Peers matched on 210 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
MedImmune sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 210 archived trials
- OHSU Knight Cancer Institute · 211 trials · 17% recruiting
- University of Louisville · 217 trials · 21% recruiting
- National Center for Complementary and Integrative Health (NCCIH) · 203 trials · 3% recruiting
- The University of Texas Medical Branch, Galveston · 203 trials · 14% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this MedImmune page
210 registered trials is a research-attention snapshot, not an endorsement of MedImmune or any single study.
- None of MedImmune's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy is the condition MedImmune studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. MedImmune pipeline card: 210 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.